Lactiplantibacillus plantarum as a potential adjuvant and delivery system for the development of sars-cov-2 oral vaccines

Julio Villena, Chang Li, Maria Guadalupe Vizoso-Pinto, Jacinto Sacur, Linzhu Ren, Haruki Kitazawa

Research output: Contribution to journalReview articlepeer-review

Abstract

The most important characteristics regarding the mucosal infection and immune responses against the Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) as well as the current vaccines against coronavirus disease 2019 (COVID-19) in development or use are revised to emphasize the opportunity for lactic acid bacteria (LAB)-based vaccines to offer a valid alternative in the fight against this disease. In addition, this article revises the knowledge on: (a) the cellular and molecular mechanisms involved in the improvement of mucosal antiviral defenses by beneficial Lactiplantibacil-lus plantarum strains, (b) the systems for the expression of heterologous proteins in L. plantarum and (c) the successful expressions of viral antigens in L. plantarum that were capable of inducing protective immune responses in the gut and the respiratory tract after their oral administration. The ability of L. plantarum to express viral antigens, including the spike protein of SARS-CoV-2 and its capacity to differentially modulate the innate and adaptive immune responses in both the intestinal and respiratory mucosa after its oral administration, indicates the potential of this LAB to be used in the development of a mucosal COVID-19 vaccine.

Original languageEnglish
Article number683
JournalMicroorganisms
Volume9
Issue number4
DOIs
Publication statusPublished - 2021

Keywords

  • Antiviral immunity
  • COVID-19
  • Immunobiotics
  • Lactiplantibacillus plantarum
  • Mucosal immunity
  • Recombi-nant lactobacilli
  • SARS-CoV-2
  • Vaccine

ASJC Scopus subject areas

  • Microbiology
  • Virology
  • Microbiology (medical)

Fingerprint

Dive into the research topics of 'Lactiplantibacillus plantarum as a potential adjuvant and delivery system for the development of sars-cov-2 oral vaccines'. Together they form a unique fingerprint.

Cite this